



## **A-TANGO**

**Novel treatment of acute on chronic liver failure  
using synergistic action of G-CSF and TAK  
H2020 – 945096**

# **D7.7 First Helix Event targeted to industry end-users and investors**

WP Leader: Nina Donner, PhD (11 - concentris)

Author: Nina Donner, PhD (11 - concentris)

Version Final Deliverable Report

Due date of deliverable 31/08/2025

Actual submission date 01/09/2025

Dissemination level Public (PU)

## Table of Contents

<b>Abbreviations .....</b>	<b>2</b>
<b>1 Executive Summary.....</b>	<b>3</b>
<b>2 Introduction.....</b>	<b>3</b>
2.1 About the A-TANGO project: Novel treatment of acute-on-chronic liver failure using synergistic action of G-CSF and TAK-242.....	3
2.2 About the Liver Health Helix.....	4
2.3 Helix Events .....	4
<b>3 Description of the Event.....</b>	<b>5</b>
3.1 Planning, Agenda, and Preparation of the First Helix Event .....	5
3.2 Registration and Communication to promote the First Helix Event .....	6
3.3 Summary of the First Helix Event .....	9
<b>4 Conclusion .....</b>	<b>11</b>
<b>5 Acknowledgement and Disclaimer .....</b>	<b>11</b>
<b>6 Appendix – Background Movie Slides .....</b>	<b>12</b>

## Abbreviations

<b>ACLF</b>	acute-on-chronic liver failure
<b>AH</b>	alcoholic hepatitis
<b>Charité</b>	Charité – Universitätsmedizin Berlin
<b>concentris</b>	concentris research management gmbh
<b>D</b>	Deliverable
<b>DisCo</b>	Dissemination and Communication
<b>DoA</b>	Description of Action
<b>EASL</b>	European Association for the Study of the Liver
<b>EC</b>	European Commission
<b>EU</b>	European Union
<b>G-CSF</b>	granulocyte-colony stimulating factor
<b>G-TAK</b>	combinatorial therapy of A-TANGO using G-CSF and TAK-242
<b>LUMC</b>	Leiden University Medical Center
<b>PU</b>	public
<b>Q&amp;A</b>	questions & answers
<b>SC</b>	Steering Committee
<b>SMEs</b>	small and medium-sized enterprises
<b>srAH</b>	steroid-resistant alcoholic hepatitis
<b>TAK-242</b>	antagonist of toll-like receptor 4 (TLR4)
<b>TLR4</b>	toll-like receptor 4
<b>UCL</b>	University College London
<b>UK</b>	United Kingdom
<b>WP</b>	work package

## 1 Executive Summary

This document outlines the **First Helix Event (Deliverable D7.7)**, the planning, organisation and implementation activities involved. Helix Events aims to connect and promote the outputs, results, and uptake of A-TANGO's innovations during and after the end of the project. These activities, including the two Helix Events, are mapped under **Task 7.3** of A-TANGO's Description of Action (DoA): Dissemination for scientists, medical and industrial community. In alignment with the overall objectives of work package 7 (WP7), the First Helix Event focused on **face-to-face interaction** with important stakeholders from industry and science during the annual and internationally renowned [EASL Congress](#) from **7-10 May 2025**, which attracted close to **8,000 attendees**.

We informed about the A-TANGO approach and our ambition to bring the combinatorial G-TAK therapy to the market. We also aimed to attract potential investors from industry who also attend the congress (in 2025, there were 78 industry sponsors, 22 industry satellite symposia, and 66 exhibition stands at [EASL Congress](#)) for implementation of the G-TAK therapy in case of a successful clinical trial.

We purposefully organised both Helix Events (First and Second) shortly after one another to

- address both the **on-site** liver research community and industry members at EASL Congress (this First Helix Event, D7.7) as well as those stakeholders who prefer an online event (Second Helix Event, see publicly available deliverable report D7.11),
- **bundle our efforts** to reach potential investors during this critical phase of the project (start of the clinical study),
- and **raise highest-possible awareness** of the urgent need to develop an effective therapy for people suffering from liver failure.

## 2 Introduction

### 2.1 About the A-TANGO project: Novel treatment of acute-on-chronic liver failure using synergistic action of G-CSF and TAK-242

Alcoholic liver disease is the most frequent cause of liver cirrhosis and a major non-communicable chronic disease. In Europe, it accounts for **6.5% of all deaths** and **30-40% of liver-related deaths**. The economic impact reaches a total of 125 billion Euros per year in Europe. The patients that are at highest risk of death are those with superimposed alcoholic hepatitis (AH), who do not respond to therapy and develop acute-on-chronic liver failure (ACLF), a newly described, severe syndrome characterised by multiorgan failure. A clinically efficacious and cost-effective therapy remains an urgent unmet need to treat patients with steroid-resistant AH (srAH) who progress to develop ACLF. Without new treatments, patients with srAH will continue to have high mortality rates.

Based upon their clinical and pre-clinical studies, the A-TANGO consortium partners have discovered a novel and innovative solution to address the problem of ACLF in patients with srAH. **G-TAK – a new combinatorial therapy** is based upon the synergy between **granulocyte-colony stimulating factor (G-CSF)** and **TAK-242, a toll-like 4 receptor (TLR4) antagonist**, which modulates inflammation. In addition, A-TANGO aims to develop novel biomarkers for patient selection and defining prognosis. Moreover, A-TANGO strives to understand the multifaceted pathophysiological basis of alcoholic hepatitis and ACLF with the fundamental aim to reduce the high mortality rates of the disease, improve quality of life for these patients, and reduce healthcare costs.

## 2.2 About the Liver Health Helix

Crowdhelix is a global network of research and technology organizations, associations, corporates, small- and medium-size companies (SMEs), and experts. The network has more than **820 members** and **18.900 expert users** on its platform. It forges links between its members and users so that they can plan, deliver, and exploit pioneering collaborative projects and value chains.

The Network is set up around thematic areas, e.g., Health Helix, Digital Helix, Energy Helix, Food Helix, etc., and is supported by Crowdhelix's digital platform, where **55 virtual communities** are hosted. A Helix is a specialised community/cluster comprising experts and research and innovation professionals across academia and industry. It provides its members with the following main functionalities:

- Announcements
- Posting of Collaboration opportunities / Dissemination opportunities
- Posting of Results
- Training and Events
- Offering Expertise
- Interaction with Experts / Organisations
- Search engine for identifying suitable collaborators (e.g. for upcoming Horizon Europe Calls)

The [Liver Health Helix](#) has been created within the framework of the A-TANGO project to accelerate the project's dissemination, communication, and commercialization strategies to build a strong, self-sustaining community of like-minded stakeholders that have access to updates on the project and collaborate with experts in their field of interest.

Since the beginning of the project, the Liver Health Helix has accumulated **333 experts from 150 organisations across 39 countries**. The Liver Health Helix is an important multiplier of A-TANGO's messages and outputs. It supports collaboration and dissemination of key results to accelerate the impact of its community of specialists in the fields of liver disease from cirrhosis, hepatology, drug manufacturing, bioinformatics, and related disciplines.

## 2.3 Helix Events

The Helix Events within the A-TANGO project are aimed to share the project's results with relevant stakeholders and targeted research and industry communities. Wherever possible, the consortium creates networking opportunities to facilitate interaction with stakeholders, especially through the two Helix Events that were planned during the duration of the project. These events aimed to bring together participants from both the research community and industry to discuss the findings and potential applications of the research conducted in A-TANGO.

With this objective in mind, concentris together with Crowdhelix, Yaqrit (event sponsor), the European Association for the Study of the Liver (EASL), University College London (UCL), the Charité – Universitätsmedizin Berlin (Charité), and Leiden University Medical Center (LUMC) organised the First Helix Event **“A-TANGO Investigator & Industry Session: New solutions to address the unmet need of patients suffering from acute-on-chronic liver failure (ACLF)”** on **Thursday, 8<sup>th</sup> May 2025, from 17:00 – 19:00, in Room D202 (Level 2, Elicium Building)** at the EASL Congress venue *RAI Amsterdam*.

Key objectives of the event were:

- To communicate and disseminate A-TANGO project's aims and approach
- To discuss A-TANGO's approach and clinical trial with experienced colleagues from the liver research community
- To showcase the Liver Health Helix and attract new Helix members

### 3 Description of the Event

#### 3.1 Planning, Agenda, and Preparation of the First Helix Event

Work package 7 leader concentris initiated the planning, registration, and preparation of the event, actively involving partners Crowdhelix, Yaqrit, EASL, UCL, and the Charité during the planning stage via regular meetings of the steering committee (SC) and dissemination and communication (DisCo) committee. During these meetings, the **event agenda** was discussed and decided, **target audiences and speakers** were defined, and **organisational details** clarified. From February 2025 to May 2025, the First Helix event was planned during various Zoom conferences of the project coordination team, the SC, and the WP7 “DisCo” team. Concentris, Crowdhelix, and Yaqrit spearheaded the planning, preparation, and promotional efforts for the event. Academic partners UCL, Charité, and LUMC were tasked with revising the agenda and preparing the talks. We also decided on an “**ACLF expert panel**”, including an early-career scientist (ECS) and an invited guest speaker. See **Figure 1** for details of the final agenda. Print copies of the agenda (one per chair) were also distributed at the event.



EASL Congress  
Amsterdam, NL  
7<sup>th</sup> – 10<sup>th</sup> May 2025

**A-TANGO**

## A-TANGO Investigator & Industry Session

“New solutions to address the unmet need of patients suffering from acute-on-chronic liver failure (ACLF)”

**Thursday, 8<sup>th</sup> May, 17:00 – 19:00 h**

Room D202 (Level 2, Elidium Building) or join online: [Zoom Link](#)  
Sponsor: Yaqrit Ltd. (project member of A-TANGO)

**17:00 Welcome by the scientific coordinator of A-TANGO**  
What is A-TANGO, where are we at, and today's agenda  
Rajiv Jalan (UCL)  
10 min

**17:10 What is needed to develop new treatments for ACLF patients?**  
More personalised approaches are needed  
Rajiv Jalan (UCL)  
10 min presentation + 10 min discussion

**17:30 Exciting new developments in the treatment of ACLF**  
Where A-TANGO fits in: The G-TAK study  
Cornelius Engelmann (Charité)  
10 min presentation + 10 min discussion

**17:50 Short Break (10 min)**

**18:00 Expert Panel: What have we learned about ACLF at EASL Congress 2025**  
Chairs: Rajiv Jalan (UCL), Cornelius Engelmann (Charité)  
Speakers: Annarein Kerbert (LUMC), Nipun Verma (Chandigarh, India) & Friends  
30 min presentation + 10 min discussion

**18:40 Network & Enjoy the Catering!**  
Liver Health Helix & Who is who in the A-TANGO consortium

**19:00 End of Investigator & Industry Session**

- Read more about A-TANGO in our info brochure
- Follow us on social media
- Subscribe to receive our newsletter on [a-tango.eu](mailto:a-tango.eu)

[a-tango.eu](mailto:a-tango.eu) @a-tango.bsky.social A-TANGO on LinkedIn




 This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945096. The agenda reflects only the speakers views and the European Commission is not responsible for any use that may be made of the information it contains.

**Figure 1.** Screenshot of the final agenda of the First Helix Event, which attendees also received as print-outs placed on the venue chairs. Scientific Coordinator, Prof. Rajiv Jalan (UCL), welcomed the audience and defined the urgent need for treatment of ACLF patients. Clinical Study Supervisor Prof. Cornelius Engelmann (Charité) described the approach of A-TANGO and the complimentary actions of the combinatorial G-TAK treatment (TAK-242 + G-CSF). After exciting discussions with fellow hepatologists in the audience during the Q&A sessions following both talks, an expert panel consisting of early-career scientists Dr. Annarein Kerbert (from Leiden University Medical Center, LUMC) and invited external expert Dr. Nipun Verma (from Chandigarh Hospital, India) summarised topically related, novel ACLF results that were presented at EASL Congress 2025. The Helix event concluded with a final discussion round and socialising with event attendees (clinicians, basic researchers, and industry members). Event sponsor: The catering was organised and paid for by consortium partner Yaqrit Ltd. (United Kingdom, UK).

### 3.2 Registration and Communication to promote the First Helix Event

As the project management office and WP7 leader, concentris was best positioned to create a [registration form](#) via for the First Helix Event on *Google Forms* to a) estimate the number of attendees (so enough catering could be ordered in advance), and b) have an overview of the type of registrants (clinicians, basic scientists, industry, other). The registration form (see **Fig. 2, Top**) was initially set up as a hybrid event to also allow online attendance, but the event was later changed to “attendance only” because all registrants intended to attend the event in person anyhow (see **Fig. 2, Bottom**).



**A-TANGO**

### Investigator & Industry Session (Hybrid)

**"New solutions to address the unmet need of patients suffering from ACLF"**

Let's gather to speak about novel approaches to tackle acute-on-chronic liver failure (ACLF) and plan the start of the G-TAK study. The first 1.5 hours will be filled with scientific presentations and discussions, while the last 30 min will be more informal and can be used for networking, spinning ideas, and enjoying the catering!

**When:** Thursday, 8th May 2025, from 17:00 – 19:00 h

**Where:**

- At EASL Congress 2025 in Amsterdam, NL
- Room D202 (Level 2, Elicium Building)

You are not attending EASL Congress in person?  
No problem: You can join online via Zoom (*registration is required to receive the Zoom link*).

More information (agenda, speakers, directions) will follow soon!  
Please follow A-TANGO on [LinkedIn](#) and [Bluesky](#) for updates on the event.

Project Website: [a-tango.eu](http://a-tango.eu)

\* Indicates required question

First name \*

Your answer

Last name \*

Your answer

Email \*

Your answer

Institution (University/Company) \*

Your answer

Attendance \*

☐ On site (attending in person)

☐ Online via Zoom (link will be provided in due time)

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945096. The registration form reflects only the organisers' view and the European Commission is not responsible for any use that may be made of the information it contains.

Title	First name	Last name	Email	Institution (University/Company)	Attendance
Dr.				concentris	On site (attending in person)
				concentris	On site (attending in person)
Prof.				Univ Lille	On site (attending in person)
Dr.				Leiden University Medical Center	On site (attending in person)
Dr.				Johns Hopkins University school of medicine	On site (attending in person)
Mr.				Yaqrit	On site (attending in person)
Dr.				CTI Clinical Trial and Consulting	On site (attending in person)
Prof.				University Hospital Bern	On site (attending in person)
Mr.				HepQuant	On site (attending in person)
Dr.				HepQuant	On site (attending in person)
Prof.				HepQuant LLC	On site (attending in person)
Dr.				Quayside Research	On site (attending in person)
Prof.				Uni Leipzig	On site (attending in person)
Prof.				UCL	On site (attending in person)
Prof.				Charité	On site (attending in person)
Dr. med.				Charité	On site (attending in person)
Prof.				LUMC	On site (attending in person)
Mr.				Wits	On site (attending in person)
Dr.				LK Stockerau	On site (attending in person)
Mrs.				Yaqrit Ltd	On site (attending in person)
Dr.				Cambridge University	On site (attending in person)
Dr.				Apollo Therapeutics	On site (attending in person)
Dr.				Apollo Therapeutics Limited	On site (attending in person)
Ms.				CrowdHelix	On site (attending in person)
Dr.				GENFIT SA	On site (attending in person)
Prof.				NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY	On site (attending in person)
Dr.				Genfit	On site (attending in person)

**Figure 2.** Top: A Google Forms website was created for stakeholders (study site investigators, clinicians and scientists, industry members, and others) via Email, website, and Social Media to register for the event. Bottom: 27 attendees registered (14 industry members, 11 clinicians/scientists, 2 other). Some attended spontaneously.



Next, partners concentris, Crowdhelix, and Yaqrit were preparing and sharing the promotional communication and dissemination activities about the First Helix event. The promotional materials were then shared on social media, on EASL's communication channels, on the Crowdhelix platform, and on the project website. They were also shared by partners via their own communication channels. Please see screenshots below for examples of visuals and posts announcing the event (**Figures 3-5**).



24 March 2025

## Investigator & Industry Session on Thursday, 8 May 2025

Join us on Thursday, 8 May 2025, from **17:00-19:00 h** at EASL Congress in Amsterdam, NL, for the A-TANGO Investigator & Industry Session. You are cordially invited to participate either in person (**Room D202, level 2, Elicium Building**) or online (the Zoom Link will be sent via email after registration has been completed). Topic: New solutions to address the unmet need of cirrhosis patients suffering from acute-on-chronic liver failure (ACLF). After a brief welcome by Scientific Coordinator Prof. Rajiv Jalan, a presentation on the need for more personalised treatments for ACLF patients will follow. Dr. Cornelius Engelmann will then speak about how A-TANGO's G-TAK study ties into this. After a short break, an expert panel featuring leading researchers will discuss novel insights on ACLF from the EASL Congress 2025. Attendance is free, but please **register here** (registration closes two days prior, on 6 May). Catering (food and drinks) will be provided. The event is sponsored by consortium partner **Yaqrit**.

**Figure 3.** Prominent post about the First Helix Event (titled “Investigator and Industry Session: New Solutions to address the unmet need of patients suffering from acute-on-chronic liver failure (ACLF)”) on the homepage of the A-TANGO project.



**Figure 4.** Square visual (based on the “tulip” background design of EASL Congress 2025) to announce the First Helix Event on the project’s social medial channels and to share with partners.



**A-TANGO**  
401 followers  
4mo • Edited •

Save the date & register now (registration closes on May 6th): <https://lnkd.in/d3aRSDa5>

Join us for the A-TANGO **#Investigator** & **#Industry** Session on Thursday, 8 May, from 17:00-19:00 h at EASL Congress in Amsterdam (NL). You are cordially invited to participate either in person (Room D202, level 2, Elicium Building) or online (the Zoom Link will be sent to you in due time via email after the registration has been completed).

- ✓ Topic: New solutions to address the unmet need of **#cirrhosis** patients suffering from acute-on-chronic **#LiverFailure** (**#ACLF**)
- ✓ Chair: **Rajiv Jalan** (UCL) and **Cornelius Engelmann** (Charité)
- ✓ Catering (food and drinks) will be provided

The event is sponsored by A-TANGO partner **Yaqrit** Ltd. Attendance is free of charge, but registration is required (see link above).

**#hepatology #EASLCongress #GTAK #CombinatorialTherapy**

European Foundation for the Study of Chronic Liver Failure (EF CLIF)  
EASL | The Home of Hepatology  
European Liver Patients' Association - ELPA

Sponsored by A-TANGO consortium member

**YAQRIT**

Chaired by

  
**Rajiv Jalan**  
(UCL)

  
**Cornelius Engelmann**  
(Charité)

**A-TANGO**

#EASLCongress  
easlcongress.eu

18

2 comments · 10 reposts

**A-TANGO Project** @a-tango.bsky.social · 3mo  
Last chance to register: [docs.google.com/forms/d/e/1F...](https://docs.google.com/forms/d/e/1F...)

Don't miss out 🥰. It also includes an

👉 Expert Panel: What have we learned about acute-on-chronic **#LiverFailure** **#ACLF** at **#EASLCongress** 2025

[@easlnews.bsky.social](#)  
[@europeliver.bsky.social](#)  
[@decision4liver.bsky.social](#)  
**#LiverSky**  
**#cirrhosis**

**A-TANGO Project** @a-tango.bsky.social · 4mo  
Please register now:  
[docs.google.com/forms/d/e/1F...](https://docs.google.com/forms/d/e/1F...)

Join us for the A-TANGO **#Investigator** & **#Industry** Session on Thursday, 8 May, from 5-7 pm at **#EASLCongress**. You can participate in person or online (Zoom Link will be set via email). **#cirrhosis #LiverFailure #GTAK**

✓ Food & drinks provided 🍽️

**Welcome by the scientific coordinator**  
What is A-TANGO & Where are we at

**What is needed to develop new treatments for ACLF patients?**  
More personalised approaches

**Exciting new developments in the treatment of ACLF**  
Where A-TANGO fits in: The G-TAK study

**Expert Panel:**  
What have we learned about ACLF at EASL Congress 2025

 **Network & Enjoy the Catering!**

**A-TANGO**

#EASLCongress  
easlcongress.eu

0:06

4

6

**Figure 5.** Video-clips and posts promoting the event were shared on A-TANGO's [LinkedIn](#) (left side) and [BlueSky](#) (right side) accounts. The event posts also increased the number of followers on the new BlueSky account after the consortium had unanimously decided to close down the project's X account in early 2025.

### 3.3 Summary of the First Helix Event

The 2h-long First Helix Event, titled “A-TANGO Investigator & Industry Session: New solutions to address the unmet need of patients suffering from acute-on-chronic liver failure (ACLF)”, took place during [EASL Congress](#) in Room D202 of the Elicium Building (building complex belonging to the *RAI Convention Center* in Amsterdam, the Netherlands) on Thursday, 8<sup>th</sup> May 2025, from 17:00-19:00 h.

While **27 people** had registered in advance, the actual attendance of the event was a bit higher - fluctuating between **30-35 people** throughout the session because several people decided to join spontaneously. We still had spots open as the catering was prepared for up to 40 attendees. The reason for the fluctuation was that at such large conferences like EASL Congress (8,000 attendees overall) other sessions of interest will always take place simultaneously. In our case, this meant that some attendees were only able to join the first half of the session while others came a bit later and only joined the second part of the session. Amongst the registered attendees were international renowned hepatology experts from 10 different academic institutions (clinics and universities) and 8 different companies (industry members). See **Table 1** for details.

Industry	Academia	N.A.
Apollo Therapeutics (2)	Cambridge University (1)	other (1)
concentris (2)	Chandigarh Hospital (1)	other (1)
Crowdhelix (1)	Charité (2)	
CTI Clinical Trial & Consulting (1)	Johns Hopkins University (1)	
Genfit SA (2)	Leiden University Medical Center (1)	
HepQuant (3)	Nanfang Hospital SMU (1)	
Quayside Research (1)	Universität Leipzig (1)	
Yaqrit (2)	University College London (1)	
	University Hospital Bern (1)	
	University Lille (1)	

**Table 1.** Overview of registered attendees of A-TANGO’s First Helix Event


The event started with a cordial welcome about “What is A-TANGO? Where are we at? And today’s agenda” by the A-TANGO project coordinator **Dr. Rajiv Jalan, UCL**, and was followed by three in-depth presentations:

**Presentation 1 – Rajiv Jalan, UCL:**

*Pitfalls in developing drugs for ACLF*

*“New solutions are needed in the clinical stratification of cirrhosis patients”*

The first presentation outlined the urgent need for new treatments for patients suffering from ACLF, a condition **with high mortality and limited therapeutic options**. It highlighted the A-TANGO consortium’s Phase 2 study of the combinatorial therapy **G-TAK**, which aims to reduce inflammation and stimulate liver regeneration. Key themes included challenges in clinical trial design, the shortcomings of existing scoring systems (such as the organ failure score *CLIF-OF*), and the introduction of the **A-TANGO score** to improve patient selection and outcome prediction. The talk emphasized the importance of regulatory alignment, robust endpoints, and increased academic and industry funding to drive forward effective ACLF therapies (**Figure 6**).



**Figure 6.** Prof. Rajiv Jalan introducing the A-TANGO project and speaking about the urgent need for better patient stratification and novel treatment solutions for ACLF patients.

## Presentation 2 – Cornelius Engelmann, Charité:

### *New insights into the diagnosis and treatment of ACLF*

#### *“The A-TANGO score & the G-TAK study: A novel combinatorial therapy to treat ACLF”*

The second presentation placed A-TANGO’s clinical G-TAK trial in the wider context of ACLF research. It reviewed past therapeutic failures, including immunomodulators, regenerative therapies, and extracorporeal liver support, illustrating the complexity of ACLF and the need for multifaceted treatment strategies. Prof. Engelmann presented the rationale for combining **G-CSF** with the **TLR-4 inhibitor TAK-242**, a synergy designed to both control inflammation and enhance hepatocyte (liver cell) regeneration. This dual approach was presented as a promising candidate in the evolving spectrum of ACLF therapies, bridging the gap between supportive care, disease mechanism targeting, and liver transplant prioritisation (**Figure 7**).



**Figure 7.** Prof. Cornelius Engelmann reviewing the reasons why a lot of former therapeutic efforts may have failed and explaining the added value of A-TANGO’s G-TAK trial and the synergistic action between G-CSF and TAK-242, and approach that strives to address the underlying biological mechanisms of ACLF.



### Presentation 3 – Annarein Kerbert, LUMC, Nipun Verma, Chandigarh (India) et al.:

The final presentation summarised new insights into ACLF research from the **EASL Congress 2025**. It considered **approximately 80 abstracts** covering the pathophysiology, ACLF management, and novel therapies, with particular focus on pre-clinical and clinical advances (**Figure 8**) Highlights include studies on ammonia reduction (ornithine phenylacetate + TAK-242), recombinant ADAMTS13 for kidney protection, long-term albumin therapy (PRECIOSA trial), G-CSF efficacy in HBV-ACLF, and growth hormone/IGF-1 modulation. These findings demonstrated the progress in both the mechanistic understanding and the therapeutic development in ACLF research, reinforcing the potential of targeted interventions and combination strategies such as G-TAK.



**Figure 8.** A-TANGO early-career scientist Dr. Annarein Kerbert from LUMC (left) and invited guest speaker and Dr. Nipun Verma from Chandigarh, India (middle), went through approximately 80 abstracts (that were submitted for and presented for the first time during EASL Congress 2025) and highlighted noteworthy studies and results that may drive the ACLF field forward in the search for new and effective therapies. Each attendee received a welcome package consisting of the printed event agenda, the A-TANGO info brochure, and a bag of tasty peanuts.

During the socialising at the end (enjoying Yaqrit-sponsored catering treats in the area in front of the conference room), an A-TANGO-promoting video look (produced by concentris) was played as a loop displaying basic facts and information about the project, and inviting attendees to scan QR codes leading to the project website, to subscribe to the project's social media channels ([BlueSky](#), [LinkedIn](#), and [YouTube](#)), and to join the [Liver Health Helix](#) (maintained by Crowdhelix). See Appendix for details.

## 4 Conclusion

The First Helix Event successfully served as an interactive face-to-face event for connecting A-TANGO members with fellow researchers and clinicians, but – equally as important – also with industry members, sparked active discussions (e.g. with regard to the so-called *A-TANGO score* and the novel proposed *G-TAK treatment for ACLF*), and informed attendees about A-TANGO's aims, approach, results, status of the clinical trial (currently starting), and the potential impact of the study. Following the event, concentris shared a **summary video of the event** (see [BlueSky](#) or [LinkedIn](#)) and shared the slide decks of the presentations via email with all registered participants. Additionally, participants were invited to subscribe to the A-TANGO and Crowdhelix newsletters – thus, further increasing project-related dissemination, networking, and collaboration.

## 5 Acknowledgement and Disclaimer

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945096 (A-TANGO). This report reflects only the authors' view and the European Commission is not responsible for any use that may be made of the information it contains.

## 6 Appendix – Background Movie Slides



**EASL CONGRESS**

**Investigator & Industry Session**

*New solutions to address the unmet need of patients suffering from acute-on-chronic liver failure (ACLF)*

**Thursday, 8 May**  
**17:00 – 19:00 h**  
 Room D202  
 (Level 2, Elicium Building)

**A-TANGO**

Amsterdam, the Netherlands

#EASLCongress  
 easlcongress.eu

### A-TANGO – Featuring G-TAK

**A novel combinatorial therapy for acute-on-chronic liver failure**




- ✓ **10 million** cases of **decompensated cirrhosis** worldwide
- ✓ Effective treatment of acute-on-chronic liver failure (ACLF) is an urgent and unmet need
- ✓ A-TANGO performs **Phase II clinical studies** of G-TAK, an innovative therapeutic strategy that aims to
  - **reduce inflammation** and
  - **improve hepatocyte proliferation**
- ✓ A-TANGO also strives to **identify reliable biomarkers** for better patient stratification and increased survival



## A-TANGO – Featuring G-TAK

A novel combinatorial therapy for acute-on-chronic liver failure



www.a-tango.eu

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945096.



## A-TANGO Facts – Duration, funding, management

The project in a nutshell



- **Full project title** Novel treatment of acute-on-chronic liver failure using synergistic action of G-CSF\* and TAK-242\*\*
- **Start date** 1st March 2021
- **Duration** 5 years + possible extension
- **Funding** 6 million €
- **Members** 13 institutions in 8 European countries
- **Scientific coordination** Rajiv Jalan (University College London)
- **Study supervisor** Cornelius Engelmann (Charité, Berlin)
- **Project management** concentris research management gmbh



\*G-CSF = granulocyte colony-stimulating factor

\*\*TAK-242 = antagonist of toll-like receptor 4

www.a-tango.eu

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945096.





## The A-TANGO Consortium – On the map

13 partners, one goal – helping cirrhosis patients



[www.a-tango.eu](http://www.a-tango.eu)

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945096.



## A-TANGO Facts – Work packages (WPs)

Eight different areas of expertise



- **WP1** Regulatory issues, contracts, and ethics
- **WP2** Drug and placebo manufacturing, packaging, distribution, and disposal
- **WP3** Randomized, controlled trial of “G-TAK” in srAH\* and ACLF\*\* patients
- **WP4** Biobanking and determination of biomarkers from patient samples
- **WP5** Data management and statistical analysis of the RCT\*\*\*
- **WP6** Health economics, reimbursement, exploitation, and sustainability
- **WP7** Dissemination, communication, and training
- **WP8** Project management



\*srAH = steroid-resistant alcoholic hepatitis

\*\*ACLF = acute-on-chronic liver failure

\*\*\*RCT = randomized controlled trial

[www.a-tango.eu](http://www.a-tango.eu)

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945096.



## The Consortium – Academia & Industry

Focused expertise and collaboration




[www.a-tango.eu](http://www.a-tango.eu)

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945096.



## The Consortium – Who we are & What we do

We tango together to fight ACLF



[www.a-tango.eu](http://www.a-tango.eu)

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945096.



## Join the Liver Health Helix

Boosting the impact of liver failure research



313 Experts  
142 Organizations  
38 Countries



115 RTOs  
27 Corporations  
7 Experts  
2 Associations



ca. 10,000 users  
can be notified

powered by  
**Crowdhelix**

- The Liver Health Helix is a **global virtual community of experts** created and curated on the Crowdhelix open innovation. It brings together specialists in liver disease, particularly cirrhosis, hepatology, drug manufacturing, bioinformatics, and related disciplines for joint collaboration.
- Members of the Helix are informed about project updates, post new **collaboration opportunities**, share events and results of different projects in the field, and offer expertise to the community.
- The Helix is **open to all stakeholders and experts in the field**, establishing a self-sustaining community beyond the project's duration.



Scan to  
join helix



[www.a-tango.eu](http://www.a-tango.eu)

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945096.



## A-TANGO Online – For more information

Visit our project website and follow us on social media

• **Website**

[a-tango.eu](http://a-tango.eu)



• **YouTube**

[@a-tango\\_eu](https://www.youtube.com/@a-tango_eu)



• **Bluesky**

[@a-tango.bsky.social](https://bsky.app/profile/a-tango.bsky.social)



• **LinkedIn**

[linkedin.com/company/a-tango](https://www.linkedin.com/company/a-tango) (@a-tango)



Scan to  
access  
website



[www.a-tango.eu](http://www.a-tango.eu)

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945096.





**A-TANGO says thank you for coming today**  
**Great to see you, let's stay in touch!**



[www.a-tango.eu](http://www.a-tango.eu)

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945096.

